The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients

Autor:	Finn T. Black, Ulrik Stenz Justesen, Lars Mathiesen, Åse Bengård Andersen, I.M. Hansen, J. Gerstoft, Niels Anders Klitgaard, Court Pedersen
Rok vydání:	2005
Předmět:	Adult Male medicine.medical_specialty HIV Infections Pharmacology Gastroenterology Drug Administration Schedule chemistry.chemical_compound Pharmacokinetics immune system diseases Internal medicine medicine Humans Pharmacology (medical) Prospective Studies Adverse effect Nelfinavir Ritonavir Cholesterol business.industry Health Policy virus diseases HIV Protease Inhibitors biochemical phenomena metabolism and nutrition Middle Aged Viral Load Lipids Confidence interval Regimen Infectious Diseases chemistry HIV-1 Drug Therapy Combination Female business Lipoprotein medicine.drug
Zdroj:	HIV medicine. 6(5)
ISSN:	1464-2662
Popis:	Objectives To evaluate the long-term pharmacokinetics and safety of adding ritonavir 100 mg twice-daily to a nelfinavir 1250 mg twice-daily regimen in HIV-infected patients. Methods This was a prospective, randomized, open-label, controlled 24-week study. Sixteen patients receiving a nelfinavir 1250 mg twice-daily regimen with plasma viral load
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::370c5a272dbaa0e6444926c1b291b2b7 https://pubmed.ncbi.nlm.nih.gov/16156881 Zobrazit plný text záznamu Plný text ve formátu PDF